Richard Douglas, a director of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), reported a direct purchase of 70,000 shares of the company's common stock on March 19, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The shares were acquired at $1.40 each, bringing the total outlay to $98,000.
The purchase followed a sharp decline in Aldeyra's share price, which had fallen roughly 56% over the prior week and was trading near its 52-week low of $1.07 at the time of the filing. After the transaction, Douglas' direct holdings in the company rose to 195,000 shares. The stock subsequently recovered to $1.81, which represents a swift uplift relative to the price paid in the director's trade.
Alongside the insider purchase, Aldeyra faces important regulatory and operational developments. The U.S. Food and Drug Administration issued a Complete Response Letter regarding the company's New Drug Application for reproxalap, a candidate intended to treat dry eye disease. In its letter, the agency said the application lacked substantial evidence from well-controlled investigations and pointed to inconsistencies across study results, calling into question the reliability of the drug's demonstrated effectiveness.
The FDA did not request new clinical trials, but it extended the Prescription Drug User Fee Act (PDUFA) date to March 16, 2026, and asked Aldeyra to submit a Clinical Study Report from a prior trial. These regulatory actions constitute a material obstacle to reproxalap's approval timeline and may affect the company's near-term prospects in the program.
Market reactions and analyst coverage have been mixed. BTIG left a Buy rating on Aldeyra with a price target of $9.00, while H.C. Wainwright lowered its stance to Neutral and cut its price target to $2.00. Separately, analysis from InvestingPro cited in the company's reporting suggested the stock appears undervalued at current levels and noted Aldeyra holds more cash than debt on its balance sheet.
On the leadership front, Aldeyra announced that Stephen G. Machatha, Ph.D., the company's chief development officer, will step down by March 2026. The company said Dr. Machatha will remain through a transition period to assist with handing off his duties.
Taken together, the insider purchase, the FDA's Complete Response Letter, the mixed analyst guidance, and the announced departure of a senior development executive highlight a period of heightened uncertainty for Aldeyra. The director's buy signals a personal vote of confidence in the company's valuation or prospects, even as regulatory and organizational challenges persist.